Personalized ADHD drug shows promise in early trial for teens
NCT ID NCT02286817
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tested a drug called NFC-1 in 30 adolescents aged 12-17 with ADHD who also have specific genetic changes affecting brain receptors. The goal was to check the drug's safety and how the body processes it, while also looking for signs it might reduce ADHD symptoms. Participants received a single dose followed by four weeks of daily treatment, with results compared to a placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NFC-1 (a drug targeting glutamate receptors in the brain)
What this could lead to
If successful, this could point toward a personalized treatment for ADHD in teens with specific genetic changes.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so results may not apply widely. The drug may not improve ADHD symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT/HYPERACTIVITY DISORDER(ADHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University, Clinical Research Unit
Philadelphia, Pennsylvania, 19107, United States